Hypereosinophilic Syndrome Drug Market Comprehensive Insight by Growth Rate, Industry Status, Forecast till 2027

The global hypereosinophilic syndrome drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Hypereosinophilic syndrome (HES) is a group of blood disorders. It occurs due to the high numbers of eosinophils or white blood cells. Over time, the excess eosinophils enter various tissues which eventually damages the organs. The major factor driving the market growth include the increasing prevalence of hypereosinophilic syndrome across the globe. Moreover, the market is also growing owing to the promising pipeline drugs. Additionally, high diagnostic rates coupled with improvement in healthcare facilities are propelling the market growth. However, the market growth is hampered due to the limited revenue opportunities coupled with high treatment costs.

To Request a Sample of our Report on Hypereosinophilic Syndrome Drug Market: https://www.omrglobal.com/request-sample/hypereosinophilic-syndrome-drug-market

Some major players operating in the market include Bristol-Myers Squibb Co., GlaxoSmithKline Plc, and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2020, GlaxoSmithKline plc (GSK) announced the approval of Nucala (mepolizumab) from the US Food and Drug Administration (FDA). It is used for the treatment of Hypereosinophilic Syndrome (HES) for more than six months without an identifiable non-haematologic secondary cause in adult and paediatric patients aged 12 years and older.

Market Coverage

• The market number available for - 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

Segment Covered-

· By Type

· By Application

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Bristol-Myers Squibb Co., GlaxoSmithKline Plc, and Novartis International AG, among others.

(Get 15% Discount on Buying this Report)

A full Report of Hypereosinophilic Syndrome Drug Market is Available @ https://www.omrglobal.com/industry-reports/hypereosinophilic-syndrome-drug-market

Global Hypereosinophilic Syndrome Drug Market Report by Segment

By Type

· Benralizumab

· Dasatinib

· Dexpramipexole Dihydrochloride

· Mepolizumab

· Others

By Application

· Hospital

· Clinic

· Others

Global Hypereosinophilic Syndrome Drug Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.